Copyright
©The Author(s) 2020.
World J Clin Cases. Nov 6, 2020; 8(21): 5172-5179
Published online Nov 6, 2020. doi: 10.12998/wjcc.v8.i21.5172
Published online Nov 6, 2020. doi: 10.12998/wjcc.v8.i21.5172
Table 5 Comparison of toxic and side effects between the two groups, n (%)
| Toxic and side effects | S-1 group (n = 47) | Gemcitabine group (n = 47) | χ2 | P value |
| Granulocytopenia | 26 (55.32) | 38 (80.85) | 14.998 | 0.001 |
| Nausea and vomiting | 20 (42.55) | 33 (70.21) | 15.555 | 0.001 |
| Diarrhea | 8 (17.02) | 23 (48.94) | 23.048 | 0.001 |
| Thrombocytopenia | 23 (48.94) | 26 (55.32) | 0.816 | 0.366 |
- Citation: Cheng XW, Leng WH, Mu CL. Efficacy and safety of S-1 maintenance therapy in advanced non-small-cell lung cancer patients. World J Clin Cases 2020; 8(21): 5172-5179
- URL: https://www.wjgnet.com/2307-8960/full/v8/i21/5172.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v8.i21.5172